580 related articles for article (PubMed ID: 8855941)
41. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Carroll RC; Lockhart MS; Taylor FB
J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies.
Raut S; Gaffney PJ
Thromb Haemost; 1996 Jul; 76(1):56-64. PubMed ID: 8819252
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases.
Quesada AR; Barbacid MM; Mira E; Fernández-Resa P; Márquez G; Aracil M
Clin Exp Metastasis; 1997 Jan; 15(1):26-32. PubMed ID: 9009103
[TBL] [Abstract][Full Text] [Related]
44. Cross-linked alpha s gamma t-chain hybrids in plasma clots studied by 1D- and 2D electrophoresis and western blotting.
Grøn B; Filion-Myklebust C; Bjørnsen S; Haidaris P; Brosstad F
Thromb Haemost; 1993 Sep; 70(3):438-42. PubMed ID: 8259545
[TBL] [Abstract][Full Text] [Related]
45. Biological behavior of higher molecular weight products of fibrinolysis.
Chang ML; Bang NU
J Lab Clin Med; 1977 Jul; 90(1):216-26. PubMed ID: 874368
[TBL] [Abstract][Full Text] [Related]
46. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies.
Bini A; Mesa-Tejada R; Fenoglio JJ; Kudryk B; Kaplan KL
Lab Invest; 1989 Jun; 60(6):814-21. PubMed ID: 2659890
[TBL] [Abstract][Full Text] [Related]
47. [Influence of end products of plasmin-mediated hydrolysis of fibrinogen and fibrin (EF and Ef fragments) on fibrinogen cross-linking].
Leonova VB; Rozenfel'd MA; Biriukova MI; Kostanova EA; Vasil'eva MV
Izv Akad Nauk Ser Biol; 2002; (5):522-7. PubMed ID: 12400374
[TBL] [Abstract][Full Text] [Related]
48. Fibrinogen/fibrin degradation products (FDP/fdp). Characterization, anticoagulant activity, and influence on laboratory assays.
Arnesen H
J Oslo City Hosp; 1977 Jun; 27(6):69-80. PubMed ID: 142131
[No Abstract] [Full Text] [Related]
49. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.
Dempfle CE; Dollman M; Lill H; Puzzovio D; Dessauer A; Heene DL
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):79-86. PubMed ID: 8457657
[TBL] [Abstract][Full Text] [Related]
50. [Monomerization of the fragment D dimer of stabilized fibrin by a secretion from the medicinal leech salivary gland].
Zavalova LL; Kuzina EV; Levina NB; Baskova IP
Biokhimiia; 1992 Mar; 57(3):468-72. PubMed ID: 1344197
[TBL] [Abstract][Full Text] [Related]
51. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo.
McQuibban GA; Gong JH; Wong JP; Wallace JL; Clark-Lewis I; Overall CM
Blood; 2002 Aug; 100(4):1160-7. PubMed ID: 12149192
[TBL] [Abstract][Full Text] [Related]
52. Evidence of intramolecular cross-linked A alpha.gamma chain heterodimers in plasma fibrinogen.
Siebenlist KR; Mosesson MW
Biochemistry; 1996 May; 35(18):5817-21. PubMed ID: 8639542
[TBL] [Abstract][Full Text] [Related]
53. Fibrinogen Haifa: fibrinogen variant with absence of protective effect of calcium on plasmin degradation of gamma chains.
Soria J; Soria C; Samama M; Tabori S; Kehl M; Henschen A; Nieuwenhuizen W; Rimon A; Tatarski I
Thromb Haemost; 1987 Jun; 57(3):310-3. PubMed ID: 2958955
[TBL] [Abstract][Full Text] [Related]
54. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9.
Ochieng J; Fridman R; Nangia-Makker P; Kleiner DE; Liotta LA; Stetler-Stevenson WG; Raz A
Biochemistry; 1994 Nov; 33(47):14109-14. PubMed ID: 7947821
[TBL] [Abstract][Full Text] [Related]
55. [Detection of fibrinolysis in chronic subdural hematoma].
Trappe A; Hafter R; Wendt P; Graeff H; Blümel G
Neurochirurgia (Stuttg); 1986 May; 29(3):78-82. PubMed ID: 3724938
[TBL] [Abstract][Full Text] [Related]
56. Orientation of the carboxy-terminal regions of fibrin gamma chain dimers determined from the crosslinked products formed in mixtures of fibrin, fragment D, and factor XIIIa.
Siebenlist KR; Meh DA; Wall JS; Hainfeld JF; Mosesson MW
Thromb Haemost; 1995 Oct; 74(4):1113-9. PubMed ID: 8560422
[TBL] [Abstract][Full Text] [Related]
57. [Properties of 2 fibrin monomer forms which differ in the degree of thrombin activation. Relation of these 2 forms to specific polymerization inhibitors].
Lugovskoi EV; Tsariuk LA; Gogolinskaia GK; Derzskaia SG; Belitser VA
Biokhimiia; 1978 Jul; 43(7):1162-6. PubMed ID: 698303
[TBL] [Abstract][Full Text] [Related]
58. Plasma cross-linked fibrin degradation product (XLFbDP) assays in an in vivo model of fibrinolysis.
Rowbotham BJ; Whitaker AN; Masci PP
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):653-61. PubMed ID: 2133245
[TBL] [Abstract][Full Text] [Related]
59. [Apo B, fibrinogen-fibrin and fibronectin in the intima of the normal human aorta and large arteries and in atherosclerosis].
Shekhonin BV; Tararak EM; Samokhin GP; Vinogradov DV; Kotelianskiĭ VE
Arkh Patol; 1990; 52(4):16-21. PubMed ID: 2201275
[TBL] [Abstract][Full Text] [Related]
60. Lymphocyte suppressive peptides from fibrinogen are derived predominantly from the A alpha chain.
Plow EF; Edgington TS
J Immunol; 1986 Sep; 137(6):1910-5. PubMed ID: 2943807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
